Dr Andrew Armstrong speaks to ecancer about his talk at ASCO GU 2026 on evaluation and definition of response and progression from trials to clinical practice.

He talks about how definitions of response and progression in clinical trials differ from what clinicians encounter in real-world practice and explains the limitations of current response criteria when applied outside controlled trial settings.

Dr Armstrong also answers if clinicians should interpret atypical responses, such as pseudoprogression or mixed responses, in routine care.


He concludes by talking about what changes are needed to ensure response evaluation frameworks remain relevant in the era of immunotherapy and targeted treatments.